2,7-Diaminomitosene
CAS: 78598-43-3
Category: Pharmaceutical Intermediates
| Purity | Research Grade ≥95% (HPLC), High-Purity Grade ≥98%, Analytical Reference Standard ≥99% (for metaboli |
| Molecular Formula | C14H16N4O4 |
| Molecular Weight | 304.3 |
| Appearance | Dark purple to red-brown or blue-violet crystalline solid (characteristic of mitosene and mitomycin-class compounds) |
| Packaging | 1mg/2mg/5mg/10mg/25mg/50mg/100mg/glass vial (for research); packaged under inert atmosphere (argon or nitrogen) to prevent oxidation; light-protected and moisture-proof containers |
| Testing Indicators | Appearance — Visual inspection (characteristic purple/red-violet color); Identification — NMR (¹H, ¹³C), FTIR, or LC-MS/MS; Purity — HPLC (C18 column, UV detection at 254–360 nm, characteristic mitosene UV-Vis spectrum with absorption maxima ~250 nm, ~310 nm, ~540 nm); Mass verification — High-resolution mass spectrometry (HRMS); Water content — Karl Fischer titration; Residual solvents — GC; Heavy metals — ICP-MS; Related substances (oxidation products, degradation products, synthetic impurities) — HPLC-MS; Reductive activation assay — Electrochemical detection or DNA alkylation assay (e.g., calf thymus DNA binding followed by HPLC analysis). |
| Storage Notes | Stored in a tightly sealed, light-protected container under inert atmosphere (nitrogen or argon) at -20°C (long-term) or 2–8°C (short-term); protected from light, moisture, oxygen, and heat; away from strong oxidizers, strong acids, strong bases, and reducing agents (unless activation is intended); handle with strict moisture and oxygen control; classified as a potential carcinogen and genotoxic agent – handle with appropriate safety precautions (gloves, fume hood, proper disposal). |
| Lead Time | days |
Used as a research chemical in cancer pharmacology and DNA alkylation studies; a synthetic derivative of the mitosene core structure found in the mitomycin family of antitumor antibiotics (e.g., mitomycin C); exhibits DNA cross-linking and alkylating activity following reductive activation; studied for structure-activity relationship (SAR) analysis of mitomycin analogs to improve therapeutic index and overcome drug resistance; used as a model compound for understanding the mechanism of bioreductive alkylating agents; not approved for clinical use (research only).